Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Scinai Immunotherapeutics Ltd.
Revenue grew 99.2% YoY; but unprofitable (net margin -633.6%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Scinai Immunotherapeutics Ltd. shows $1.31M in FY2025 revenue (+99.2% YoY), a -633.6% net margin, and -102.5% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001611747, latest 10-Q filed 2023-05-15) · EODHD · rules-based read · as of 6/18/2026, 12:41:06 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $658K | $1.31M |
| Gross profit | — | — | — | -$580K | -$2.65M |
| Operating income | -$10.9M | -$11.1M | -$9.71M | -$8.64M | -$7.54M |
| Net income | -$8.21M | -$5.80M | -$6.50M | $4.80M | -$8.31M |
| Diluted EPS | -$0.02 | $0.01 | $0.00 | — | — |
| Net margin | — | — | — | 728.9% | -633.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median